canakinumab

FDA Drug Profile — Ilaris

Drug Details

Generic Name
canakinumab
Brand Names
Ilaris
Application Number
BLA125319
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
2
Dosage Forms
INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
CANAKINUMAB

Indications and Usage

Immune support suring times of: Seasonal colds and flu

Warnings

Stop use and ask doctor if symptoms persist more than 5 days or worsen. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children.